Microbiome 2026 | Keynote by Dr Jeremiah Faith, Ichan School of Medicine at Mount Siani, USA

Value of the Information & Strength of the Argument

The talk provides valuable insights into the translational path of microbiome therapeutics, combining basic science with practical manufacturing considerations. The argumentation is strong, based on data from a clinical trial conducted by the speaker’s group, and is supported by references to larger trials (Rebiota, Vowst). The speaker clearly explains the rationale for selecting engrafting strains and the benefits of defined consortia over FMT. He also addresses potential limitations, such as the small size of his trial and the loss of strains from donors over time. The presentation is persuasive, advocating for a shift towards more human intervention studies in academia.

Scientific Rigor, Source Quality, Title Accuracy

The scientific rigor is high, as the speaker presents data from a clinical trial and references published studies. The sources are primarily his own work and major trials in the field. The title accurately reflects the content, focusing on the design, manufacture, and engraftment of live microbial therapeutics. The talk is well-structured and provides specific details on manufacturing protocols and costs, which adds to its credibility. However, as a keynote, it is an expert opinion rather than a peer-reviewed publication, and some claims are based on a single small trial.

The title accurately reflects the content: a keynote presentation on microbiome research, specifically focusing on the design, manufacture, and engraftment of live microbial therapeutics.

8/10

The talk is a keynote by a recognized expert in microbiome research, presenting results from a clinical trial conducted by his group. The methodology is described in detail, and the results are consistent with published literature. However, the talk is not peer-reviewed and some claims are based on a single small trial.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 02:00Introduction of the speaker and his background.
• 05:00Discussion on the history of microbiome research and the need for human interventions.
• 10:00Presentation of the first accomplishments: FDA-approved drugs for C. difficile (Rebiota and Vowst).
• 15:00Explanation of the concept of engraftment and its importance for therapeutic success.
• 20:00Description of the culturing facility and the process of isolating and selecting engrafting strains.
• 25:00Details of the clinical trial comparing FMT with the defined consortium MTC01.
• 30:00Results on engraftment and diversity, showing that MTC01 engrafts well but does not restore full diversity immediately.
• 35:00Discussion on microbiome stewardship and the potential benefits of defined consortia over FMT.
• 40:00Cost breakdown and timeline for setting up a manufacturing facility and conducting a clinical trial.
• 45:00Introduction of solid-state culture as a more efficient manufacturing method.

• Rebiota (fecal microbiota product) trial — Mentioned as a large randomized placebo-controlled trial for C. difficile infection.
• Vowst (fecal microbiota spores) trial — Mentioned as another FDA-approved product for C. difficile infection.
• CP101 trial — Mentioned as a large randomized placebo-controlled trial for C. difficile infection.

• Rebiota trial publication — Large trial showing efficacy of fecal microbiota product for C. difficile.
• Vowst trial publication — Large trial showing efficacy of fecal microbiota spores for C. difficile.